Richard Scott Struthers - 14 Aug 2023 Form 4 Insider Report for Crinetics Pharmaceuticals, Inc. (CRNX)

Role: President & CEO, Director
Signature: /s/ Marc Wilson, as attorney-in-fact
Issuer symbol: CRNX
Transactions as of: 14 Aug 2023
Net transactions value: +$19,100
Form type: 4
Filing time: 16 Aug 2023, 16:30:15 UTC
Previous filing: 13 Jul 2023
Next filing: 06 Nov 2023
SEC: View on sec.gov

Transactions Table

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Ownership	Footnotes
transaction	CRNX	Common Stock	Options Exercise	$19,100	+10,000	+8%	$1.91^*	135,522	14 Aug 2023	Direct
holding	CRNX	Common Stock						630,805	14 Aug 2023	By Family Trust 1
holding	CRNX	Common Stock						1,000	14 Aug 2023	By Spouse
holding	CRNX	Common Stock						90,000	14 Aug 2023	By Family Trust 2
holding	CRNX	Common Stock						90,000	14 Aug 2023	By Family Trust 3
holding	CRNX	Common Stock						90,000	14 Aug 2023	By Family Trust 4

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Underlying Class	Amount	Exercise Price	Ownership	Footnotes
transaction	CRNX	Incentve stock option (Right to Buy)	Options Exercise	$0	-10,000	-6.2%	$0.000000	151,270	14 Aug 2023	Common Stock	10,000	$1.91	Direct	F1

* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id	Content
F1	1/48th of the shares subject to the option vested on April 16, 2018, and 1/48th of the shares subject to the option vested monthly thereafter, subject to the Reporting Person's continued employment with the Issuer on each such vesting date.